Mylan NV and Teva Pharmaceutical Industries Ltd decline as report says generic-drug companies face probe of alleged price fixing
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Mylan Rejects Teva Buyout Offer
Mylan sees opportunity in rival Teva's weakness - MarketWatch
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Teva-Makes-Hostile-Bid-Acquire
Teva's recall of U.S.-made drugs latest example of contamination fears in generic marketplace; report says Lilly, Pfizer and former Mylan plant in Morgantown have been cited in the past | WV News
Mylan rejects Teva takeover bid as too low | Mint
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
$40B deal: Teva offers to buy Mylan
Teva makes $40 billion offer for Mylan
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Drugmaker Teva makes $40B bid for rival Mylan
